Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.84 |
| ▸ | CA1 | P00915 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.60 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPN | P05981 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39130 | 0.92 | CA2 (1.00) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL5669484 | 0.91 | ALOX15 (0.77) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL70237 | 0.86 | CA2 (0.80) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL10406844 | 0.86 | CA2 (0.88) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| Hydroquinone SCHEMBL7796131 | 0.84 | CA2 (0.84) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL240515 | 0.82 | CA2 (0.80) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL29602570 | 0.82 | CA2 (0.80) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| Methoxymethane SCHEMBL9777263 | 0.80 | ALDH1A1 (0.83) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL17796869 | 0.80 | CA2 (0.59) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL5090529 | 0.80 | CA2 (0.77) | CA2CA1ALDH1A1ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459578-A2 | SOLID ALKYLARYL PHOSPHITE COMPOSITIONS AND METHODS FOR MANUFACTURING SAME | Chemtura Corporation (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014527-A2 | SOLID ALKYLARYL PHOSPHITE COMPOSITIONS AND METHODS FOR MANUFACTURING SAME | Chemtura Coproration (US) | 2011-02-03 | — | — | WO | disclosed |
| EP-2118188-A1 | POLYMER COMPOSITE | EASTMAN KODAK COMPANY (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080286377-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2008-11-20 | — | — | US | disclosed |
| WO-2008094500-A1 | POLYMER COMPOSITE | EASTMAN KODAK COMPANY (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1150684-A4 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2000047214-A9 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN KETTERING INST CANCER (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-1150684-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | Sloan-Kettering Institute For Cancer Research (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047214-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286377-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SOST, BMP6, BMP2 | CA2 2655/4885CA1 1814/4885ALDH1A1 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.